Aerie Pharmaceuticals shares jump on FDA approval of glaucoma drug Rocklatan
Shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) jumped in Wednesday’s pre-market session after the US Food and Drug Administration gave the green light to its daily eye drop Rocklatan, which reduces elevated eye pressure in patients with open-angle glaucoma and ocular hypertension.
The FDA’s approval of Rocklatan comes less than a year after the successful launch of Aerie’s first glaucoma drug Rhopressa (netarsudil ophthalmic solution), which targets the eye’s principal drainage pathway, and was introduced in April of 2018.
Investors were enthusiastic about the FDA’s stamp of approval, sending Aerie shares up 5.85% to $48.50 before the opening bell Wednesday.
Rocklatan to be launched in second quarter
Glaucoma is a disease that causes damage to the optic nerve. It is characterized by the progressive degeneration of retinal cells, which results in vision loss and, potential blindness.
The Durham, North Carolina-based pharmaceutical company plans to launch Rocklatan (netarsudil and latanoprost ophthalmic solution) in the second quarter of this year.
“We are in the unique position of receiving FDA approval on a second glaucoma treatment less than a year from the U.S. launch of Rhopressa,” said Dr Vicente Anido, CEO of Aerie. “Together, Rocklatan and Rhopressa give us a broad therapeutic franchise, based on our ROCK inhibitor netarsudil, that addresses many of the needs of clinicians and patients in a wide variety of treatment settings.”
On the back of the FDA’s approval of Rocklatan, the ophthalmic pharmaceutical company announced revenue guidance for 2019 in a range of $110 million to $120 million. The forecast includes the combined net revenues for Rhopressa and Rocklatan.
In other news, Aerie says its net cash burn in 2019 is set to fall between $130 million to $140 million.
Aerie is focused on the development of therapies to treat open-angle glaucoma and other diseases of the eye.
Contact Ellen Kelleher at [email protected]
Story by ProactiveInvestors
Source: https://www.proactiveinvestors.com/companies/news/216392/aerie-pharmaceuticals-shares-jump-on-fda-approval-of-glaucoma-drug-rocklatan-216392.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Please Help Support BeforeitsNews by trying our Natural Health Products below!
Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST
Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!
HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation.
Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.
MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser! Cleans out toxic buildup with oxygen!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover - Reduces Smart Meter radiation by 96%! (See Video).